Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

Surinder S. Birring; Peter V. Dicpinigaitis; Jaclyn A. Smith; Alyn H. Morice; Lorcan P. McGarvey; Ian D. Pavord; Allison Martin Nguyen; Jonathan Schelfhout; Qing Li; Beata Iskold; Stuart A. Green; George Philip; David R. Muccino; Carmen La Rosa

doi:10.1164/rccm.202211-2128LE

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

Surinder S. Birring, Peter V. Dicpinigaitis, Jaclyn A. Smith, Alyn H. Morice, Lorcan P. McGarvey, Ian D. Pavord, Allison Martin Nguyen, Jonathan Schelfhout, Qing Li, Beata Iskold, Stuart A. Green, George Philip, David R. Muccino, Carmen La Rosa

Medicine

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	1539-1542
Number of pages	4
Journal	American journal of respiratory and critical care medicine
Volume	207
Issue number	11
DOIs	https://doi.org/10.1164/rccm.202211-2128LE
State	Published - Jun 1 2023

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine

Access to Document

10.1164/rccm.202211-2128LE

Cite this

Birring, S. S., Dicpinigaitis, P. V., Smith, J. A., Morice, A. H., McGarvey, L. P., Pavord, I. D., Nguyen, A. M., Schelfhout, J., Li, Q., Iskold, B., Green, S. A., Philip, G., Muccino, D. R., & Rosa, C. L. (2023). Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks. American journal of respiratory and critical care medicine, 207(11), 1539-1542. https://doi.org/10.1164/rccm.202211-2128LE

Birring, SS, Dicpinigaitis, PV, Smith, JA, Morice, AH, McGarvey, LP, Pavord, ID, Nguyen, AM, Schelfhout, J, Li, Q, Iskold, B, Green, SA, Philip, G, Muccino, DR & Rosa, CL 2023, 'Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks', American journal of respiratory and critical care medicine, vol. 207, no. 11, pp. 1539-1542. https://doi.org/10.1164/rccm.202211-2128LE

@article{9dba4cae9fc74c09a76e54ef1fdaec02,

title = "Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks",

author = "Birring, {Surinder S.} and Dicpinigaitis, {Peter V.} and Smith, {Jaclyn A.} and Morice, {Alyn H.} and McGarvey, {Lorcan P.} and Pavord, {Ian D.} and Nguyen, {Allison Martin} and Jonathan Schelfhout and Qing Li and Beata Iskold and Green, {Stuart A.} and George Philip and Muccino, {David R.} and Rosa, {Carmen La}",

note = "Funding Information: Acknowledgment: Medical writing support was provided by Anish Mehta of Merck & Co., Inc., Rahway, NJ. The authors thank Jennifer Pawlowski, M.S., of Merck & Co., Inc., Rahway, NJ, for editorial and administrative support. Additional editorial support was provided by Jenna Lewis, M.A., E.L.S., of MedThink SciCom, Cary, NC, and funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ. Funding Information: Supported by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ. S.S.B. receives research support from the National Institute for Health Research Wellcome King{\textquoteright}s Clinical Research Facility, National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, King{\textquoteright}s College London. J.A.S. is funded by the National Institute for Health Research Manchester Biomedical Research Centre and a Wellcome Investigator Award and is a National Institute for Health Research senior investigator. L.P.M. receives research support from the Northern Ireland Clinical Research Network and by the National Institute for Health Research Clinical Research Facilities and Clinical Research Network staff.",

year = "2023",

month = jun,

day = "1",

doi = "10.1164/rccm.202211-2128LE",

language = "English (US)",

volume = "207",

pages = "1539--1542",

journal = "American journal of respiratory and critical care medicine",

issn = "1073-449X",

publisher = "American Thoracic Society",

number = "11",

}

TY - JOUR

T1 - Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

AU - Birring, Surinder S.

AU - Dicpinigaitis, Peter V.

AU - Smith, Jaclyn A.

AU - Morice, Alyn H.

AU - McGarvey, Lorcan P.

AU - Pavord, Ian D.

AU - Nguyen, Allison Martin

AU - Schelfhout, Jonathan

AU - Li, Qing

AU - Iskold, Beata

AU - Green, Stuart A.

AU - Philip, George

AU - Muccino, David R.

AU - Rosa, Carmen La

N1 - Funding Information: Acknowledgment: Medical writing support was provided by Anish Mehta of Merck & Co., Inc., Rahway, NJ. The authors thank Jennifer Pawlowski, M.S., of Merck & Co., Inc., Rahway, NJ, for editorial and administrative support. Additional editorial support was provided by Jenna Lewis, M.A., E.L.S., of MedThink SciCom, Cary, NC, and funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ. Funding Information: Supported by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ. S.S.B. receives research support from the National Institute for Health Research Wellcome King’s Clinical Research Facility, National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, King’s College London. J.A.S. is funded by the National Institute for Health Research Manchester Biomedical Research Centre and a Wellcome Investigator Award and is a National Institute for Health Research senior investigator. L.P.M. receives research support from the Northern Ireland Clinical Research Network and by the National Institute for Health Research Clinical Research Facilities and Clinical Research Network staff.

PY - 2023/6/1

Y1 - 2023/6/1

UR - http://www.scopus.com/inward/record.url?scp=85160969396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85160969396&partnerID=8YFLogxK

U2 - 10.1164/rccm.202211-2128LE

DO - 10.1164/rccm.202211-2128LE

M3 - Letter

C2 - 36996347

AN - SCOPUS:85160969396

SN - 1073-449X

VL - 207

SP - 1539

EP - 1542

JO - American journal of respiratory and critical care medicine

JF - American journal of respiratory and critical care medicine

IS - 11

ER -

Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this